Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial-Reference-Cited by-同舟云学术

Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial

Published:2013-11 Issue:11 Volume:24 Page:2766-2772
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Jiang Z.F.,Cristofanilli M.,Shao Z.M.,Tong Z.S.,Song E.W.,Wang X.J.,Liao N.,Hu X.C.,Liu Y.,Wang Y.,Zeng L.,Zhang M.

Funder

This work was supported by Johnson & Johnson Medical Shanghai Ltd.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/11/2766/16700478/mdt246.pdf

Reference20 articles.

1. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization;Gradilone;Ann Oncol,2011

2. Circulating tumour cells in breast cancer;Ring;Lancet Oncol,2004

3. Circulating tumor cells, disease progression, and survival in metastatic breast cancer;Cristofanilli;N Engl J Med,2004

4. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer;Budd;Clin Cancer Res,2006

5. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer;Cristofanilli;J Clin Oncol,2005

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world comparison of circulating tumor cells in breast cancer from China: Novel device, CTC counts and its overall survival;Heliyon;2024-04

2. Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates (Review);Oncology Reports;2023-07-14

3. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy;Breast Cancer Research and Treatment;2023-05-25

4. Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis;2022-09-21

5. Prognostic Relevance of Estrogen Receptor Status in Circulating Tumor Cells in Breast Cancer Patients Treated With Endocrine Therapy;Frontiers in Oncology;2022-04-28